CLYM116 and A ProlifeRation Inducing Ligand (APRIL)
CLYM116 is a novel anti-APRIL mAb with a proprietary mechanism designed to promote potent degradation of APRIL and extend half-life.
APRIL plays a key role in B cell regulation, making it an attractive target for multiple B cell-mediated diseases. Targeting of APRIL has been clinically validated in registrational studies in IgA nephropathy (IgAN), a B cell-mediated immune-mediated disease; however, there is an opportunity to develop an improved clinical profile.
APRIL signaling, through its receptors, impacts B cells in key ways:
- Promotes differentiation and survival of plasma cells, the source of many pathogenic autoantibodies
- Regulates Ig class switching, the process in which mature B cells acquire expression of IgA
CLYM116 is a novel anti-APRIL mAb with a proprietary ‘Sweeper’ mechanism and Fc engineering to extend half-life and promote potent degradation of APRIL.
Designed for strong efficacy, more rapid response, and reduced dosing frequency
Novel ‘Sweeper’ mechanism:
CLYM116 Variable Region exhibits pH-dependent binding to APRIL, resulting in both potent blocking of APRIL to its receptors and promotion of lysosomal APRIL degradation
CLYM116 Fc Region engineered to promote antibody recycling and reduce clearance of CLYM116
Our CLYM116 development strategy
Nullam consectetur blandit augue, vel tempor orci faucibus a. Integer sed eros quis metus fringilla aliquam ac et ipsum. Phasellus lacinia varius enim, nec condimentum leo porttitor a. Duis nunc dolor, eleifend at ultrices sit amet, tristique vitae nisl.
Progressive Glomerula Diseases
A progressive, autoantibody-driven renal disease characterized by APRIL-mediated overproduction of IgA and glomerular deposition of immune complexes, leading to proteinuria, kidney injury, and progressive loss of renal function.
Clinical Trial
Nullam consectetur blandit augue, vel tempor orci faucibus a. Integer sed eros quis metus fringilla aliquam ac et ipsum. Phasellus lacinia varius enim, nec condimentum leo porttitor a. Duis nunc dolor, eleifend at ultrices sit amet, tristique vitae nisl.